PAH Patient Evidence Submission Survey: sotatercept

PHA Canada, along with our partners at Scleroderma Ontario, Sclerodermie Quebec, and Foundation HTAPQ, is conducting a survey to learn how current pulmonary arterial hypertension (PAH) therapies affect you and your expectations for the new PAH therapy sotatercept. You are invited to participate in this survey if you are a PAH patient or caregiver residing in Canada.

The survey results were included in the patient/caregiver input we provided to Canada/Quebec’s health technology assessment agencies – e.g., CADTH and INESSS.

The survey is now closed.

If you would like more information about the survey or our submissions regarding sotatercept, please get in touch with PHA Canada Executive Director Jamie Myrah at jmyrah@phacanada.ca.